Abstract
The additional application of low-dose rivaroxaban twice daily to standard therapy showed improved efficacy in patients with acute coronary syndrome (ACS) in the ATLAS ACS 2-TIMI 51 (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome thrombolysis in myocardial infarction) study. All-cause mortality was even reduced with 2 A~ 2.5 mg rivaroxaban. However, increased efficacy was associated with worse safety with, most importantly, an increased rate of intracranial bleeding.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
